

Pharmaceutical Benefits Advisory Committee

Email: PBAC@health.gov.au

Address all mail to:
PBAC Secretariat
GPO Box 9848
Canberra ACT 2601

DELISTING OF PHARMACEUTICAL BENEFIT ITEMS EFFECTIVE 01 DECEMBER 2023

Following is the advice of the Pharmaceutical Benefits Advisory Committee concerning the delisting of items from the declaration under subsections 85(2) and 85(2A) of the *National Health Act 1953*, with effect from the above date.

<u>Item</u>	<u>PBAC Advice</u>
Estradiol with dydrogesterone	<p>The sponsor requested the delisting of Femoston-Conti[®] (estradiol with dydrogesterone) from the Pharmaceutical Benefits Scheme (PBS).</p> <p>The PBAC noted there was a significant number of services in the last financial year. The PBAC noted that there are no suitable alternatives as it is the only low dose form of continuous menopausal hormone therapy on the PBS. The PBAC advised the delisting of this product may result in an unmet clinical need.</p>
Pancrelipase	<p>The sponsor requested the delisting of Panzytrat 25000[®] (pancrelipase) from the PBS.</p> <p>The PBAC noted the low number of services in the last financial year and that the alternative s19A product is no longer available. The PBAC noted that the sponsor advised there has been no supply of the product in Australia. The PBAC advised the delisting of this product would not result in an unmet clinical need.</p>
Sterculia with frangula bark	<p>The sponsor requested the delisting of Normacol Plus[®] (rhamnus frangula + sterculia) from the PBS.</p> <p>The PBAC noted the substantial number of services and advised it is preferable to retain as it is the only bulk forming laxative on the PBS. The PBAC advised the delisting of this product may result in an unmet clinical need.</p>

Vanessa McMahon
Director, PBAC Assessment Section
Office of Health Technology Assessment
Technology Assessment and Access Division
21 November 2023